Literature DB >> 23149328

Tumor-associated stromal cells expressing E-prostanoid 2 or 3 receptors in prostate cancer: correlation with tumor aggressiveness and outcome by angiogenesis and lymphangiogenesis.

Yasuyoshi Miyata1, Kojiro Ohba, Tomohiro Matsuo, Shin-Ichi Watanabe, Tomayoshi Hayashi, Hideki Sakai, Hiroshi Kanetake.   

Abstract

OBJECTIVE: To clarify the detailed pathologic roles of prostaglandin E(2) in prostate cancer tissues, the present study investigated the clinical significance and prognostic roles of the density of tumor-associated stromal cells expressing specific receptors for prostaglandin E2, termed "E-prostanoid (EP)1-4 receptors (EP1R-4Rs)."
METHODS: The expression of each receptor was immunohistochemically examined in 114 formalin-fixed biopsy specimens. Correlations with clinicopathologic features were investigated in these specimens. Angiogenesis and lymphangiogenesis were measured by the percentage of CD34-stained vessels (microvessel density) and D2-40-stained vessels (lymph vessel density). The relationships between the density of each EPR-stained cells and the microvessel density or lymph vessel density were evaluated in 62 prostate cancer tissues obtained by radical surgery for more detailed analysis in a wider area of prostate cancer tissue.
RESULTS: The density of tumor-associated cells with EP2R expression was positively associated with the N (P<.001) and M (P=.002) stages. Similarly, EP3R-positive stromal cell density was significantly associated with the N (P=.033) and M (P=.026) stages. The density of EP2R- and EP3R-stained cells correlated with the microvessel density (r=0.42, P<.001) and lymph vessel density (r=0.36, P=.012), respectively. A greater density of EP2R-stained cells was recognized as an independent predictor of progression (hazard ratio 7.26, P=.002) on multivariate analysis.
CONCLUSION: EP2R- and EP3R-stained cells might play important roles in tumor progression, angiogenesis, and lymphangiogenesis in prostate cancer. The density of EP2R-stained stromal cells could offer a useful predictor of biochemical recurrence after radical surgery.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149328     DOI: 10.1016/j.urology.2012.08.014

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  DDR1 enhances invasion and metastasis of gastric cancer via epithelial-mesenchymal transition.

Authors:  Ruixia Xie; Xiaoying Wang; Guoqing Qi; Zhiping Wu; Rong Wei; Peirong Li; Dekui Zhang
Journal:  Tumour Biol       Date:  2016-05-14

2.  Inflammatory lymphangiogenesis in postpartum breast tissue remodeling.

Authors:  Melody A Swartz
Journal:  J Clin Invest       Date:  2014-08-18       Impact factor: 14.808

3.  Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.

Authors:  Feiya Yang; Liming Song; Huiping Wang; Jun Wang; Zhiqing Xu; Nianzeng Xing
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  Expression of prostaglandin E2 prostanoid receptor EP2 and interleukin-1β in laryngeal carcinoma - preliminary study.

Authors:  Marcin Mochocki; Piotr Morawski; Renata Kopta; Ewa Brzezińska-Błaszczyk; Olga Stasikowska; Iwona Lewy-Trenda; Katarzyna Starska
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

Review 5.  Prostaglandin E2-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment.

Authors:  Tomohiro Aoki; Shuh Narumiya
Journal:  Inflamm Regen       Date:  2017-03-01

6.  The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.

Authors:  Helene Heidegger; Sebastian Dietlmeier; Yao Ye; Christina Kuhn; Aurelia Vattai; Caroline Aberl; Udo Jeschke; Sven Mahner; Bernd Kost
Journal:  Int J Mol Sci       Date:  2017-07-19       Impact factor: 5.923

7.  CD163 as a marker of M2 macrophage, contribute to predicte aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma.

Authors:  Jian Ming Hu; Kai Liu; Ji Hong Liu; Xian Li Jiang; Xue Li Wang; Yun Zhao Chen; Shu Gang Li; Hong Zou; Li Juan Pang; Chun Xia Liu; Xiao Bin Cui; Lan Yang; Jin Zhao; Xi Hua Shen; Jin Fang Jiang; Wei Hua Liang; Xiang Lin Yuan; Feng Li
Journal:  Oncotarget       Date:  2017-03-28

Review 8.  Vitamin D in prostate cancer.

Authors:  Donald L Trump; Jeanny B Aragon-Ching
Journal:  Asian J Androl       Date:  2018 May-Jun       Impact factor: 3.285

9.  Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.

Authors:  Yasuyoshi Miyata; Kensuke Mitsunari; Akihiro Asai; Kosuke Takehara; Yasushi Mochizuki; Hideki Sakai
Journal:  Prostate       Date:  2014-10-13       Impact factor: 4.104

10.  Microvascular density and immunohistochemical expression of VEGF, VEGFR-1 and VEGFR-2 in benign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer.

Authors:  Nikolaos Grivas; Anna Goussia; Dimitrios Stefanou; Dimitrios Giannakis
Journal:  Cent European J Urol       Date:  2016-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.